New startup ideas · Health and bio · Healthcare and bio
startup idea
Vialport
AI agents that run the vendor paperwork between pharma R&D and outsourced labs.
Vialport gives pharma and large biotech R&D operations teams a fleet of AI agents that handle the non-clinical work between a sponsor and its outsourced labs: sourcing quotes from CROs and CDMOs, chasing certificates of analysis, reconciling sample shipments and invoices, and keeping study logistics current across email, ERP and ELN.
- AI agent as a service
- Enterprise
- $100B+ market
- Platform others build on
- Global from day one
4/5
venture judge
8
similar startups, last 2 years (22 all-time)
97%
of 4 nearest real companies still alive
yes
2 matching federal grants and programs
Direction supported by government programs and grants
Test it before you build it
$1,200 · 5 weeks · 30 prospects
Prove that outsourcing managers at mid-size biotechs will prepay $1,500 for a CoA-and-quote-chasing pilot instead of routing it to their SAP integrator, for $1,200 in five weeks.
Riskiest assumption · An outsourcing manager at a mid-size biotech controls budget for vendor-paperwork chasing and will pay a startup for it, rather than treating it as an ERP configuration task that belongs to their existing SAP integrator.
1Focus group: who and where
Outsourcing manager or associate director of external research at a US biotech of 50-500 employees, running 3-10 active CRO and CDMO programs, who spent part of this month personally chasing a certificate of analysis or a re-quote across vendor inboxes
where to find 30 · BioPharmGuy's free state-by-state biotech directories filtered to clinical-stage companies in Boston and San Diego; the DCAT member directory, whose members are exactly pharma sourcing and external manufacturing people; speaker and sponsor lists from Outsourcing in Clinical Trials New England and the BioProcess International Conference in Boston; r/biotech threads complaining about CRO responsiveness
2Sell first, build later
A 30-day pilot starting within 3 weeks of payment: we chase every open quote request and certificate of analysis across your three busiest CROs, daily, and hand you a weekly status sheet; humans plus our agents do the work, you just read the sheet
the ask · $1,500 prepaid for the 30-day pilot, then $15 per closed request after go-live
a real yes · A real yes is $1,500 landed by ACH with a signed one-page order form and a start date. Not a yes: 'this is a big pain for us', an unpaid trial, or an intro to their SAP integrator
3Small experiments
The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.
1. Fifteen paid-pilot pitch calls
$950 · 14 days
Build a list of 30 named outsourcing managers from BioPharmGuy and DCAT, email each a three-line note about the CoA chase, and run 15 calls. On every call, walk through their last five open vendor requests and end with one ask: a $1,500 prepaid 30-day pilot on their three busiest CROs. Founders run every call; two day trips to Boston and San Diego for in-person meetings with the warmest five.
keep going if · 5 of 15 calls end with a scoping session booked that includes the person who owns the budget
2. One-page offer and invoice
$100 · 10 days
Send each scoped prospect a one-page order form: 30 days, three named CROs, all open quote and CoA requests worked daily, weekly status sheet, start within 3 weeks, $1,500 prepaid and refunded if fewer than 50 requests close. Attach the invoice with the order form, not after a follow-up.
keep going if · 4 of 5 scoping sessions receive the signed-order-form ask; 3 either pay or forward it to accounts payable with a named approver
3. Procurement routing test
$150 · 14 days
Track every sent invoice through the sponsor's vendor onboarding: return W-9 and vendor forms same day and log where each one stalls. This directly tests the stated risk; if invoices die in 'our IT team will look at this with our SAP integrator', that is the kill evidence, captured in writing.
keep going if · 2 of 3 accepted invoices clear vendor onboarding and money lands within 14 days
4Collect a deposit up front
Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.
$1,500
per prospect, refundable
how · Paid design-partner pilot invoiced up front: a one-page order form signed by the outsourcing manager or their VP and $1,500 by ACH before the start date. Chosen over a card checkout because a mid-size biotech budget owner can approve a sub-$2,000 services invoice without a full procurement cycle, which is itself part of the test set up: Stripe Invoicing ↗
what it reserves · One of three pilot slots in the first cohort, the sponsor's three CROs wired in first, and the $15 per closed request price locked for 12 months
refund · Refunded in full if fewer than 50 requests close in the 30 pilot days, no questions asked
target · 3 paid pilots from 15 pitch calls within 35 days
Go: build it if
3 of 15 pitched sponsors pay the $1,500 pilot and money clears onboarding within 14 days, and at least 2 pilots generate 50+ closed requests worth of live work
Kill: stop if
0 paid pilots after 15 calls and 5 sent invoices, or 5+ prospects independently say they are handing this to their existing SAP or ERP integrator
5 Scripts to run itoutreach message, landing copy, deposit terms · click to open
outreach message
If you run outsourced programs, part of last week probably went to chasing a CoA or a re-quote across three CRO inboxes. I'm signing three pilot sponsors for a service that does that chasing for you: 30 days, your three busiest CROs, every open request worked daily, $1,500 prepaid and refunded if we close fewer than 50 requests. Do you have 20 minutes this week to walk through your open request list?
landing page
Your CRO paperwork, chased daily, so your scientists never send reminder three. $1,500 for a 30-day pilot across your three busiest CROs, refunded under 50 closed requests. Book a 20-minute scoping call and pick your start date.
deposit terms
You pay $1,500 today by ACH against a one-page order form. It reserves one of three first-cohort pilot slots, a start date within 3 weeks, and a $15 per closed request price locked for 12 months. If fewer than 50 of your requests close during the 30 pilot days, the full amount is refunded.
Would you run this test?
One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.
Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
80
Idea Score, 0-100 · raw 50.0 x 1.61
Active
competition: more crowded than 47% of ideas · headwind x0.76
+1.2
government priorities, secondary (2 matching grants)
Trend
61
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)51
- Rounds announced 2025+ in the sector69
- Sector direction (live batch)100
- 2026 trend analyst25
Demand
60
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain50
100x potential
71
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge75
- Market size axis100
- Moat axis100
- Neighbours still alive76
- Technologist judge0
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were vendor, paperwork, pharma, outsourced, labs, biotech, operations, fleet.
The idea in full
- What
- Vialport gives pharma and large biotech R&D operations teams a fleet of AI agents that handle the non-clinical work between a sponsor and its outsourced labs: sourcing quotes from CROs and CDMOs, chasing certificates of analysis, reconciling sample shipments and invoices, and keeping study logistics current across email, ERP and ELN. It sells as a per-workflow subscription with a small implementation fee, sits entirely outside GxP and touches no patient data. After the first year the agent actions are exposed as an API and skill format, so instrument vendors, CROs and internal IT teams publish their own connectors on top.
- Why now
- The radar shows the outsourcing layer itself becoming a software target inside one year: Harbor (yc X26) is an AI-native CRO for trial operations and AbInitio Bio (yc X26) is an intelligence layer for drug manufacturing, while the cluster added 126 new companies in the 2024 cohort alone against 1759 all-time, so buyers now expect agents rather than dashboards.
- Wedge: first customer and entry point
- One mid-size biotech's outsourcing manager, single workflow: chasing quotes and certificates of analysis from three named CROs, priced per closed request so the first agent pays for itself in one quarter.
- Path to 100x
- Outsourced pharma R&D and manufacturing spend clears $100B a year globally, and every dollar of it moves through quotes, shipments and reconciliations that no one owns today. Winner takes most because each completed workflow teaches the agents a vendor's real turnaround, pricing and document formats, and once outside parties publish connectors against that library the graph of sponsor-to-vendor interactions is not reproducible by a second entrant.
- Ceiling
- If the ten largest CROs each ship their own free sponsor portal, Vialport is squeezed into a thin integration tool worth a few hundred million.
- Closest real companies, as the generator saw them
- Harbor replaces the CRO itself and AbInitio Bio goes deep into manufacturing intelligence; Vialport stays neutral back-office plumbing between sponsor and any vendor, which is why competing CROs will connect to it. Panacea works the regulatory filing side, not vendor operations.
- Main risk
- Pharma procurement teams treat vendor paperwork as an ERP configuration problem and hand it to their existing SAP integrator instead of a startup.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
4/5
Capital-light agents on $100B+ outsourced R&D spend with a sponsor-to-vendor interaction graph that a second entrant cannot reproduce.
Bootstrapper
4/5
Unregulated back-office paperwork priced per closed request, capital-light, with an outsourcing manager who can sign a single-workflow pilot.
Operator
3/5
Chasing certificates of analysis is real and frequent, but no one owns that paperwork budget today, which is why procurement hands it to the SAP integrator.
Technologist
1/5
Chasing quotes and certificates of analysis over email and ERP is agent glue an SAP integrator or any CRO portal absorbs.
Risk
4/5
Sits outside GxP with no patient data, sells neutral plumbing to any vendor, and per-workflow pricing survives any single CRO changing terms.
trends
2/5
Buyers-now-expect-agents is the generic 2026 claim; vendor paperwork automation was equally true in 2023 and the agent cluster is already packed.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (vendor, paperwork, pharma, outsourced, labs, biotech, operations, fleet): 22 all-time, 8 from the last two years. Same matching as Idea Check.
Nomic is doing for proteins what Illumina has done for DNA
AIoT monitoring, workflow, and evidence systems for regulated labs.
The vendor-neutral coordination and translation layer for biomanufacturing data, connecting pharma sponsors and their manufacturing partners so AI can finally scale and deliver real value.
Affordable, intelligent humanoid robots built to deploy at scale
Full-stack Service Layer for Robots and Autonomous Machines
Working capital for data companies training frontier AI
Robotic pitstops for self-driving cars
The Fastest Multimodal Inference OS
Biospecimen logistics & operations layer to accelerate drug dev
Making hard molecules for Pharma and Biotech
Charging session management for fleet EVs.
Battery Insurance for Commercial Electric Vehicles
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
2
grants and programs matching the idea
1595
startup-relevant grants in Healthcare and bio
$854M
awarded in the sector, tracked
118
opportunities open now in the sector
- A Universal Platform for Ultrahigh-Throughput Biocatalyst Evolution With micro-Mass Spectrometryawardhigh relevance
NIH / NIGMS · SBIR phase II · $307K · posted 2025-08-01
- NSF PCL-Test Bed: Towards a General Platform for AI-Driven High-Throughput Reaction Discovery and Automationawardmedium relevance
National Science Foundation · PCL-Programmable Cloud Labs · $20M · posted 2026-07-21
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 135 → 121 → 224 → 173 → 127 new companies 2022 → 2026 · 91% aliveYC F26 live: 2 in this cluster, 2% of the batch (was 6% in S26)Since February, of 442 YC companies here: 6 acquired, 6 shut down, 45 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Enterprise
- Business model
- AI agent as a service
- Path to 100x
- Platform others build on
- Market size
- $100B+ market
- Capital intensity
- Capital-light (software margins)
- Speed to revenue
- Revenue in 1-3 years
- Technical depth
- Integrations, no-code
- Go-to-market
- Founder-led sales
- Moat
- Data moat
- Geography
- Global from day one
- Regulation
- Unregulated
- Vibe
- Hot space
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Fictional company written 2026-08-22 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.